Travere Therapeutics, Inc. (TVTX)
40.77
+1.23
(+3.11%)
USD |
NASDAQ |
Apr 17, 16:00
40.80
+0.03
(+0.07%)
After-Hours: 20:00
Travere Therapeutics SG&A Expense (Quarterly) : 101.69M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Revolution Medicines, Inc. | 66.68M |
| ICU Medical, Inc. | 155.81M |
| Tandem Diabetes Care, Inc. | 113.10M |
| iRhythm Holdings, Inc. | 122.00M |
| Ligand Pharmaceuticals, Inc. | 25.03M |